Abundant Biopharma - Innovative Targeted Cancer Therapies

Next-Gen Targeted Cancer Treatments

We develop innovative therapies activating only within tumors, minimizing systemic toxicity and revolutionizing cancer care with APDC technology.

Revolutionizing Cancer Therapy Delivery

Abundant Biopharma’s proprietary APDC platform enables prodrugs to remain inactive until they reach tumor-specific environments characterized by acidic pH, hypoxia, or unique enzymes, drastically reducing off-target effects and improving patient outcomes.

Next-Gen Innovation

Precision Targeting

Enhanced Safety

Selective Activation

Prodrugs are designed to activate only within tumor micro-environments, ensuring targeted treatment.

Reduced Toxicity

Replacing highly toxic payloads with low- or non-toxic prodrugs minimizes systemic side effects.

Innovative Technology

Cutting-edge APDC platform enables safer use of potent therapeutics not feasible before.

Precision Delivery

Advanced antibody conjugation ensures medicines reach cancer cells precisely and safely.

I hereby agree that this data will be stored and processed for the purpose of establishing contact. I am aware that I can revoke my consent at any time.*

*Please fill in all the required fields.
Message was successfully sent

Get in touch

Telephone: 858-866-8774

E-mail: info@abundantbiopharma.com

Address: 6349 Nancy Ridge Dr Ste A, SAn Diego, CA 92121, USA

©Copyright of Abundant Biopharma, Inc.  All rights reserved.

Information icon

We need your consent to load the translations

We use a third-party service to translate the website content that may collect data about your activity. Please review the details in the privacy policy and accept the service to view the translations.